IR@PKUHSC  > 北京大学第二临床医学院
学科主题临床医学
Pharmacokinetics of tacrolimus converted from twice-daily formulation to once-daily formulation in Chinese stable liver transplant recipients
Zhang, Yi-fan1; Chen, Xiao-yan1; Dai, Xiao-jian1; Leng, Xi-sheng2; Zhong, Da-fang1
关键词tacrolimus modified release clinical pharmacokinetics liver transplantation
刊名ACTA PHARMACOLOGICA SINICA
2011-11-01
DOI10.1038/aps.2011.125
32期:11页:1419-1423
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Chemistry, Multidisciplinary ; Pharmacology & Pharmacy
研究领域[WOS]Chemistry ; Pharmacology & Pharmacy
关键词[WOS]MODIFIED-RELEASE TACROLIMUS ; SOLID-ORGAN TRANSPLANTATION ; PROGRAF-BASED REGIMEN ; OPEN-LABEL TRIAL ; CLINICAL-EXPERIENCE ; CONVERSION
英文摘要

Aim: To evaluate the pharmacokinetics of tacrolimus in Chinese stable liver transplant recipients converted from immediate release (IR) tacrolimus-based immunosuppression to modified release (MR) tacrolimus-based immunosuppression.

Methods: Open-label, multi-center study with a one-way conversion design was conducted. Eighty-three stable liver recipients (6-24 months post-transplant) with normal renal and stable hepatic function were converted from IR tacrolimus twice-daily treatment to MR tacrolimus once-daily treatment on a 1:1 (mg:mg) total daily dose basis. Twenty-four hour pharmacokinetic studies were carried out on d 0 (pre-conversion), d 1, and d 84 (post-conversion).

Results: The area under the blood concentration-time curve of MR tacrolimus from 0 to 24 h (AUC(0-24)) on d 1 was comparable to that of IR tacrolimus on d 0, with a 90% confidence interval (CI) for MR/IR tacrolimus of 92%-97%. The AUC(0-24) value for MR tacrolimus on d 84 with the daily dose increased by 14% was approximately 17% lower than that for IR tacrolimus. The 90% CI was 77%-90%, outside the bioequivalence range of 80%-125%. There was a good correlation between AUC(0-24) and concentration at 24 h (C(24)) for IR tacrolimus (d 0, r=0.930) and MR tacrolimus (d 1, r=0.936; d 84, r=0.903).

Conclusion: The exposure to tacrolimus when administered MR tacrolimus once daily is not equivalent to that for IR tacrolimus twice daily after an 84-day conversion in Chinese stable liver transplant recipients. The dose should be adjusted on the basis of trough levels. The therapeutic drug monitoring for patients treated with IR tacrolimus is considered to be applicable to MR tacrolimus.

语种英语
WOS记录号WOS:000296739400016
Citation statistics
Cited Times:5[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/60994
Collection北京大学第二临床医学院
作者单位1.Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China
2.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China
Recommended Citation
GB/T 7714
Zhang, Yi-fan,Chen, Xiao-yan,Dai, Xiao-jian,et al. Pharmacokinetics of tacrolimus converted from twice-daily formulation to once-daily formulation in Chinese stable liver transplant recipients[J]. ACTA PHARMACOLOGICA SINICA,2011,32(11):1419-1423.
APA Zhang, Yi-fan,Chen, Xiao-yan,Dai, Xiao-jian,Leng, Xi-sheng,&Zhong, Da-fang.(2011).Pharmacokinetics of tacrolimus converted from twice-daily formulation to once-daily formulation in Chinese stable liver transplant recipients.ACTA PHARMACOLOGICA SINICA,32(11),1419-1423.
MLA Zhang, Yi-fan,et al."Pharmacokinetics of tacrolimus converted from twice-daily formulation to once-daily formulation in Chinese stable liver transplant recipients".ACTA PHARMACOLOGICA SINICA 32.11(2011):1419-1423.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Zhang, Yi-fan]'s Articles
[Chen, Xiao-yan]'s Articles
[Dai, Xiao-jian]'s Articles
百度学术
百度学术Similar articles in
[Zhang, Yi-fan]'s Articles
[Chen, Xiao-yan]'s Articles
[Dai, Xiao-jian]'s Articles
必应学术
必应学术Similar articles in
[Zhang, Yi-fan]'s Articles
[Chen, Xiao-yan]'s Articles
[Dai, Xiao-jian]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.